We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Healthcare Inv | LSE:HIO | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMCOS
Collagen Solutions PLC
28 September 2015
Collagen Solutions Plc
(the "Company" or the "Group")
Supply Agreement with Yucel
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its subsidiary Collagen Solutions Inc. has signed a supply agreement with Turkish medical device company Yücel Medikal Ltd (Yucel)
This supply agreement covers the provision of collagen materials and support services for use in Yucel's product Lyocoll which is currently on sale in Turkey. Lyocoll is a local haemostatic used in all types of surgery to control capillary and venous bleeding as well as oozing where the conventional methods are impractical and ineffective.
Commenting on the agreement Dr Stewart White, CEO of Collagen Solutions, said: "Collagen Solutions is pleased to have signed another supply agreement with our valued customer Yucel to provide materials for their haemostatic product Lyocoll. This supply agreement further demonstrates the range of products that our medical grade collagens are suitable for and the global nature of our reach."
Senol Yucel, CEO of Yucel added: "Consistency of product and continuity of supply are two very important factors for us and we have carried out a thorough review of the capabilities of Collagen Solutions to deliver the specific collagen that we require for Lyocoll. We are therefore pleased to be able to sign this agreement with a company which we can trust to deliver a quality product for us."
Enquiries:
Collagen Solutions Plc David Evans, Chairman Tel: 07740 084 452 Stewart White, CEO Tel: 0141 648 9100 Panmure Gordon & Co (Nomad and Tel: 0207 8862 714 Broker) Tel: 0207 886 2905 Robert Naylor (Corporate Finance) Maisie Atkinson (Corporate Broking) Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: 07876 741 001 Mike Wort Mob: 07900 608 002
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGUGABUPAUAR
(END) Dow Jones Newswires
September 28, 2015 02:02 ET (06:02 GMT)
1 Year Healthcare Inv Chart |
1 Month Healthcare Inv Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
